title: Management of nasopharyngeal adenoid cystic carcinoma.
abstract: OBJECTIVE
  Nasopharyngeal adenoid cystic carcinomas (NACCs) are rare. No clear consensus is available regarding clinical characteristics and management approaches. The aim of this study was to summarize the clinical characteristics and evaluate the management approaches of NACC.
  
  
  METHODS
  The experience of 1 institution with this tumor and the outcomes of treatment were examined. The medical records of 36 patients with NACC at 1 institution from 1963 through 2006 were reviewed.
  
  
  RESULTS
  After a median follow-up of 65.8 months (1.8 to 245.2 mo), the 5- and 10-year overall survival, locoregional failure-free survival, and distant metastasis failure-free survival rates were 70.2% and 31.6%, 63.4% and 49.1%, and 65.0% and 59.6%, respectively. No significant differences were found in locoregional failure-free survival, distant metastasis failure-free survival, or overall survival rates between the group that received radiotherapy alone and the group that received combined modality therapy (radiotherapy plus surgery or surgery plus radiotherapy).
  
  
  CONCLUSIONS
  NACC is a malignancy with a generally favorable prognosis. Radiotherapy alone or a combined modality therapy (radiotherapy plus surgery or surgery plus radiotherapy) is effective in the treatment of NACC.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
authors.forename: Cai-Neng
authors.initials: CN
authors.lastname: Cao
authors.forename: Jing-Wei
authors.initials: JW
authors.lastname: Luo
authors.forename: Guo-Zhen
authors.initials: GZ
authors.lastname: Xu
authors.forename: Li
authors.initials: L
authors.lastname: Gao
authors.forename: Zhen-Gang
authors.initials: ZG
authors.lastname: Xu
authors.forename: Ping-Zhang
authors.initials: PZ
authors.lastname: Tang
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D003390:Cranial Nerve Neoplasms / Q000556:secondary; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D009361:Neoplasm Invasiveness; D017239:Paclitaxel / Q000627:therapeutic use; D010166:Palliative Care; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel